The FTSE 100 has closed the week in the green, after receiving a boost from oil majors and miners. The blue-chip index rose 0.34pc to finish at 7,464.54. The FTSE
Block Energy PLC (AIM:BLOE) Completion of Drilling Operations on well WR-34Z
Successful Completion of Drilling Operations on well WR-34Z
Block Energy PLC (AIM:BLOE) Spud of WR-34Z
Block Energy plc, the development and production company focused on Georgia, is pleased to announce it has spud its next Project I development well, WR-34Z.
RNS Hotlist with Zak Mir: BOOM, THX, TEK, CRDL, BLOE, SNT, ALK, ZEN, FMET, MSMN, THR, UOG & HARL
This post was written by Zak Mir, a Technical Analyst, Events Host, Presenter, CEO Interviewer and established Market Commentator.
Share Talk Weekly Stock Market News Review, Sunday 16th April 2023
Overall, the AIM All-Shares index had a positive week, with a more than 2% increase in share price, outperforming the FTSE 100. Friday’s closing bell, the FTSE 100 resumed its
RNS Hotlist with Zak Mir: WBI, BLOE, MXC, AAA, HERC, 88E, EDL, UKOG, DKL, GST & SEED
This post was written by Zak Mir, a Technical Analyst, Events Host, Presenter, CEO Interviewer and established Market Commentator.
Block Energy PLC (AIM:BLOE) MoU with Ministry of Economy and Sustainable Development of Georgia
Block Energy plc, the exploration and production company focused on Georgia, is pleased to announce that it has entered into a Memorandum of Understanding (“MoU”) with the Ministry of Economy
Block Energy PLC (AIM:BLOE) Corporate Update
Termination of Salary Sacrifice
RNS Hotlist with Zak Mir: ANA, ENSI, SYM, FRAN, ECO, FCM, PTAL, BLOE, VRCI, TLOU, AFC, FRG & SYN
This post was written by Zak Mir, a Technical Analyst, Events Host, Presenter, CEO Interviewer and established Market Commentator.
Block Energy PLC (AIM:BLOE) Completion of Farm-Out Agreement
Block Energy plc, the exploration and production company focused on Georgia, announces completion of the farm-out of part of licence XIB to Georgia Oil and Gas Limited (“GOG”).
RNS Hotlist with Zak Mir: OKYO, BRSD, CCZ, BOIL, ESYS, TM1, BLOE, ABDX & UOG via Vox Markets
OKYO Pharma (OKYO), an ophthalmology-focused bio-pharmaceutical company, announced that its GMP packaged OK-101 drug to be used in the upcoming Phase 2, first-in-human, clinical trial in patients with DED, which